Pasar al contenido principal

DISEÑO Y SINTESIS DE NUEVOS INHIBIDORES MEJORADOS DE COLINA QUINASA COMO POTENCIALES FARMACOS CON ACTIVIDAD ANTIPROLIFERATIVA.

SAF2009-11955

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Nacional de Proyectos de Investigación Fundamental
Subprograma Subprograma de Proyectos de Investigación Fundamental no Orientada
Convocatoria Proyectos I+D
Año convocatoria 2009
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Subdirección General de Proyectos de Investigación
Centro beneficiario UNIVERSIDAD DE GRANADA
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The mechanism of allosteric coupling in choline kinase α1 revealed by the action of a rationally designed inhibitor

  • Sahún-Roncero, M.
  • Rubio-Ruiz, B.
  • Saladino, Giorgio
  • Conejo-García, A.
  • Espinosa, Antonio
  • Velázquez-Campoy, Adrián
  • Gervasio, Francesco Luigi
  • Entrena, Antonio
  • Hurtado-Guerrero, Ramón
5 pags, 4 pags. -- Supporting information for this article (experimental details) is available on the WWW under http://dx.doi.org/10.1002/anie.201209660., Applying a CHOK hold: Combined experimental and computational studies of the binding mode of a rationally designed inhibitor of the dimeric choline kinase α1 (CHOKα1) explain the molecular mechanism of negative cooperativity (see scheme) and how the monomers are connected. The results give insight into how the symmetry of the dimer can be partially conserved despite a lack of conservation in the static crystal structures. Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim., We thank the Fundación Agencia Aragonesa para la Investigación y el Desarrollo (ARAID, Spain), the Ministerio de Economía y Competitividad (MEC, Spain, grants BFU2010-19504, BFU2010-19451, SAF2009-11955, and BIO2010-20166), the Consejería de Innovación, Ciencia y Empresa of the Junta de Andalucía (grant P07-CTS-03210), the Ministerio de Educación for a FPU fellowship (AP2007-03115) to B.R.-R., and Diputación General de Aragón (Grupo Protein Targets, B89) and the Comunidad Autónoma de Madrid S2010-BMD-2457 (BIPEDD2). This work was granted access to the HPC resources of HECToR, within the Distributed European Computing Initiative (FP7/2007-2013, RI-283493).
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Design, synthesis, crystallization and biological evaluation of new symmetrical biscationic compounds as selective inhibitors of human Choline Kinase a1 (ChoKa1)

  • Schiaffino-Ortega, S.
  • Baglioni, E.
  • Mariotto, E.
  • Bortolozzi, R.
  • Serrán-Aguilera, L.
  • Riós-Marco, P.
  • Carrasco-Jimenez, M.
  • Gallo, M.A.
  • Hurtado-Guerrero, R.
  • Marco, C.
  • Basso, G.
  • Viola, G.
  • Entrena, A.
  • López-Cara, L.C.
A novel family of compounds derivative of 1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))-bispyridinium or-bisquinolinium bromide (10a-l) containing a pair of oxygen atoms in the spacer of the linker between the biscationic moieties, were synthesized and evaluated as inhibitors of choline kinase against a panel of cancer-cell lines. The most promising compounds in this series were 1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-(dimethylamino)pyridinium) bromide (10a) and 1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))-bis(7-chloro-4-(pyrrolidin-1-yl)quinolinium) bromide (10l), which inhibit human choline kinase (ChoKa1) with IC 50 of 1.0 and 0.92 Î 1/4M, respectively, in a range similar to that of the previously reported biscationic compounds MN58b and RSM932A. Our compounds show greater antiproliferative activities than do the reference compounds, with unprecedented values of GI 50 in the nanomolar range for several of the cancer-cell lines assayed, and more importantly they present low toxicity in non-tumoral cell lines, suggesting a cancer-cell-selective antiproliferative activity. Docking studies predict that the compounds interact with the choline-binding site in agreement with the binding mode of most previously reported biscationic compounds. Moreover, the crystal structure of ChoKa1 with compound 10a reveals that this compound binds to the choline-binding site and mimics HC-3 binding mode as never before.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Pharmacophore-Based Virtual Screening to Discover New Active Compounds for Human Choline Kinase a1

  • Serrán-Aguilera, L.
  • Nuti, R.
  • Lõpez-Cara, L.C.
  • Mezo, M.Á.G.
  • Macchiarulo, A.
  • Entrena, A.
  • Hurtado-Guerrero, R.
Choline kinase (CK) catalyses the transfer of the ATP gamma-phosphate to choline to generate phosphocholine and ADP in the presence of magnesium leading to the synthesis of phosphatidylcholine. Of the three isoforms of CK described in humans, only the a isoforms (HsCK alpha) are strongly associated with cancer and have been validated as drug targets to treat this disease. Over the years, a large number of Hemicholinium-3 (HC-3)-based HsCK alpha biscationic inhibitors have been developed though the relevant common features important for the biological function have not been defined. Here, selecting a large number of previous HC-3-based inhibitors, we discover through computational studies a pharmacophore model formed by five moieties that are included in the 1-benzyl-4-(N-methylaniline) pyridinium fragment. Using a pharmacophore-guided virtual screening, we then identified 6 molecules that showed binding affinities in the low mM range to HsCK alpha 1. Finally, protein crystallization studies suggested that one of these molecules is bound to the choline and ATP-binding sites. In conclusion, we have developed a pharmacophore model that not only allowed us to dissect the structural important features of the previous HC-3 derivatives, but also enabled the identification of novel chemical tools with good ligand efficiencies to investigate the biological functions of HsCK alpha 1.